Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Equillium, Inc. (EQ)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/06/2022 |
8-K
| Quarterly results |
| 09/27/2022 |
8-K
| Investor presentation |
| 09/06/2022 |
8-K
| Investor presentation|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Equillium, Inc., Metacrine, Inc., Equillium Acquisition Sub, Inc., and Triumph Merger Sub, Inc",
"Equillium to Acquire Metacrine in All-Stock Transaction",
"Investor Presentation" |
|
| 02/16/2022 |
8-K
| Investor presentation|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED AGREEMENT AND PLAN OF MERGER by and among Equillium, Inc.; Project JetFuel Merger Sub, Inc.; Bioniz Therapeutics, Inc. and Kevin Green, as the Securityholders' Representative Dated as of February 14, 2022 TABLE OF CONTENTS PAGE SECTION 1. DESCRIPTION OF TRANSACTION 1 1.1 The Merger 1 1.2 Effect of the Merger 1 1.3 Closing; Effective Time 2 1.4 Certificate of Incorporation and Bylaws; Directors and Officers 2 1.5 Conversion of Shares 2 1.6 Treatment of Company Options. 3 1.7 Further Action 3 1.8 Closing of the Company's Transfer Books 3 1.9 Exchange/Payment 4 1.10 Post-Closing Adjust...",
"Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates",
"Corporate Presentation" |
|
| 04/30/2019 |
8-K
| Investor presentation |
| 11/13/2018 |
8-K
| Investor presentation |
|
|